Expand all sections

Brain cancer vaccine

DCVax-L

Extended indication Glioblastoma multiforme, 1L adjuvant.
Therapeutic value No judgement

Product

Active substance Brain cancer vaccine
Domain Oncology and Hematology
Main indication Brain cancer
Extended indication Glioblastoma multiforme, 1L adjuvant.
Proprietary name DCVax-L
Manufacturer Northwest
Route of administration Intrader meal
Therapeutical formulation Injection
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Orphan drug Yes

Therapeutic value

Therapeutic value No judgement
Duration of treatment Not found

Expected patient volume per year

Patient volume

< 708

Market share is generally not included unless otherwise stated.
References NKR
Additional remarks NKR 2015: 708 diagnoses glioblastoom

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.